Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Hayashibara is a prominent Japanese biotechnology company specializing in the development and manufacture of functional carbohydrates and bioactive substances. Founded in 1883 and headquartered in Okayama, the company gained international acclaim for its proprietary enzymatic technology used to mass-produce trehalose, a sugar with unique preservative properties. In addition to food and cosmetic ingredients, Hayashibara produces pharmaceutical-grade materials, including high-purity maltose and natural human interferon-alpha. Following its acquisition by Nagase & Co. in 2012, the company continues to innovate in the life sciences sector as a key member of the Nagase Group.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Hayabashi Biochemical Labs.